Lab resource: stem cell line

Peripheral blood mononuclear cell-converted induced pluripotent stem cells (iPSCs) from an early onset Alzheimer’s patient

Han-Kyu Lee a,b, Peter Morin b, Weiming Xia b,*

a Department of Neurology, Rhode Island Hospital and Brown University Warren Alpert Medical School, 593 Eddy Street, Providence, RI, United States
b Geriatric Research, Education and Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, United States

Abstract

Improvement in transduction efficiency makes it possible to convert blood cells into induced pluripotent stem cells (iPSC). In this study, we generated an iPSC line from peripheral blood mononuclear cells (PBMC) donated by a patient who exhibited memory deficit at age 59; outcome of positron emission tomography scan is consistent with a diagnosis of Alzheimer’s disease. Integration-free CytoTune-iPS Sendai Reprogramming factors which include Sendai virus particles of the four Yamanaka factors Oct4, Sox2, Klf4, and c-Myc were introduced to PBMC to convert them to iPSCs without retention of virus. Three germ layer differentiation was induced to demonstrate the pluripotency of these iPSCs.

Resource table

| Name of stem cell construct | I2-12F |
|----------------------------|-------|
| Institution                | Edith Nourse Rogers Memorial Veterans Hospital |
| Person who created resource | Han-Kyu Lee, Weiming Xia |
| Contact person and email   | Weiming Xia, Weiming.Xia@va.gov |
| Date archived/stock date   | May 14, 2015 |
| Origin                     | Human peripheral blood mononuclear cells (PBMCs) |
| Type of resource           | Induced pluripotent stem cell (iPS); derived from human peripheral blood mononuclear cells (PBMCs) |
| Sub-type                   | Induced pluripotent stem cell (iPS) |
| Key transcription factors  | Oct4, Sox2, cMyc, Klf4 |
| Authentication             | Identity and purity of cell line confirmed (Fig. 2) |
| Link to related literature (direct URL) | Not available |
| Information in public databases | Not available |

2. Resource details

The blood sample was donated by the patient who was hospitalized at the Bedford VA Hospital Special Dementia Care Unit, which is a hospice unit staffed and managed by the Bedford Geriatric Research, Education and Clinical Center (GRECC).

The patient exhibited memory deficit at age 59 that prevented him from performing job-related function. Subsequent neurological tests and positron emission tomography (PET) scan presented clinical diagnosis consistent with Alzheimer’s disease. The patient also suffered two witnessed seizures which were controlled by anti-epileptic drug levetiracetam. The study was approved by the Bedford Veterans Affairs Hospital Institutional Review Board under the project title, “iPSC for Neurodegenerative diseases”.

Peripheral blood mononuclear cells (PBMC) were separated from whole blood and transduced by reprogramming vectors carrying four Yamanaka factors, Oct4, Sox2, Klf4, and c-Myc included in the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen). The four Yamanaka factors have been well documented for efficient reprogramming of skin fibroblasts and blood cells (Trokovic et al., 2014; Lieu et al., 2013; Takahashi et al., 2007).

We confirmed development of human iPSC by karyotyping (Fig. 1), which is a standard procedure to authenticate normal karyotypes of cells (Li et al., 2011). To validate bona fide iPSCs in our culture that is distinguishable from only partially transduced cells, we examined the expression of cell surface proteins, such as sialylated keratan sulfate antigens Tra-1-81 and Tra-1-60, which defines a human embryonic stem cell (Badcock et al., 1999; Nethercott et al., 2011; Sommer et al., 2012). Immunocytochemical staining using antibody against stem cell marker Tra-1-81 (Fig. 2A) and Tra-1-60 (not shown) was performed to confirm the purity and pluripotency of our iPSC.

Many approaches have been developed to produce footprint-free iPSC (Ovchinnikov et al., 2015), and we applied the CytoTune-iPS 2.0 Reprogramming System for our studies (Seki et al., 2010). This system

http://dx.doi.org/10.1016/j.scr.2015.12.050
1873-5061/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
uses vectors that remain in the cytoplasm (Li et al., 2000) and do not integrate into host genome (Fusaki et al., 2009). Therefore, the host cell can be cleared of the vectors and reprogramming factor genes (Li et al., 2000). We searched for any remaining SeV protein by immunocytochemical staining using Anti-SeV antibody (MBL international) and confirmed that there is no trace of viral protein (Fig. 2B).

To demonstrate capacity of iPSC for three germ layer differentiation, we tested formation of embryoid body (EB) (Hribar et al., 2015). We performed immunostaining using three different antibodies corresponding to three germ layers, i.e., ectoderm: βIII tubulin antibody, mesoderm: smooth muscle actin (SMA) antibody, endoderm: α-fetoprotein (AFP) antibody. Our results demonstrated differentiation capacity of newly converted iPSC (Fig. 3).

3. Materials and methods

3.1. Human blood sample

Blood was collected in Vacutainer cell preparation tube (CPT) (Becton, Dickinson and Company, Franklin Lakes, NJ). PBMCs were prepared within 1 h of blood collection. Blood samples were centrifuged at 1500 rcf for 20 min at room temperature, and the PBMCs were collected.
and transferred to a fresh tube, washed with PBS, and centrifuged at 300 rcf for 10 min at room temperature. Cell pellets were re-suspended in PBMC medium (Invitrogen) containing growth factors for transduction.

3.2. iPSC generation and expansion

Induced iPSCs were generated from freshly collected, peripheral blood-derived PBMCs (Chou et al., 2011). Cells were transduced with Sendai virus particles containing four Yamanaka factors using the integration-free CytoTune-iPS Sendai Reprogramming Kit (Lieu et al., 2013; Takahashi et al., 2007). Transduced cells were plated with mouse embryonic fibroblast (MEF) feeder cells. Cells were fed with iPSC medium containing bFGF (Invitrogen) until small colonies were formed in 2 weeks. Growth of small colonies was maintained for another two weeks before each colony was picked for expansion into individual iPSC lines. After successful formation of iPSC colonies, iPSCs were transferred to plates coated with Geltrex (Invitrogen) and expanded in EB medium (Invitrogen).

3.3. Live staining of iPSC

Purity and pluripotency of iPSCs grown on both MEF feeder cells and Geltrex coated plates were confirmed by live staining with Tra-1-81 and Tra-1-60 antibodies (Invitrogen). Cells were washed with Knockout DMEM and stained with Tra-1-81 or Tra-1-60 antibodies at 1:200 dilutions for 1 h in the CO2 incubator. Cells were subsequently washed twice with Knockout DMEM and incubated with secondary anti-mouse antibody conjugated with Alexa Fluor 488 for one hour. Finally, cells were washed with Knockout DMEM and replenished with iPSC growth medium for microscopic imaging. Images were acquired using a Leica TCS SP5 Confocal Laser Scanning Microscope.

3.4. iPSC karyotyping

Karyotyping of the iPSC was carried out at the CytoGenomics Core Laboratory (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA). G-banding was used to karyotype our iPSC line. Cells in a stage of active division in metaphase were arrested, harvested and transferred to plates coated with Geltrex (Invitrogen) and expanded in EB medium (Invitrogen). Individual nuclei were imaged (Olympus BX51, 100×) and counted using the Cyto Vision Software.

3.5. Three germ layer in vitro differentiation and characterization

The differentiation capability of iPSC lines was analyzed by the formation of EB, based on the previously published protocol (Carpenter et al., 2003; Itoivovitz-Eldor et al., 2000). Briefly, undifferentiated iPSC colonies were transferred into the non-adherent poly-HEMA (Sigma) coated petri dish and were cultured in E6 medium without bFGF for 7 days. The resulting EB, which theoretically comprise three embryonic germ layers, were plated onto Geltrex coated tissue culture dishes and cultured for spontaneous differentiation. After cells were differentiated in EB culture for a total of 19 days, cells were fixed with 4% PFA and immuno-stained with three different antibodies (Ectoderm: β III tubulin, Sigma; Mesoderm: Smooth muscle actin, Invitrogen; Endoderm: Alpha fetoprotein, Invitrogen). Images were acquired using the Nikon TMS, 10×; the Leica TCS SP5 Confocal Microscope, 10×; and the AmScope microscope digital camera.

4. Verification and authentication

Karyotyping of our iPSC was performed and revealed by the microscope scan. All ten metaphase cells had 46 chromosomes and had XY sex chromosomes characteristic of a male patient (Fig. 1).

We examined embryonic stem cell makers, Tra-1-81 and Tra-1-60 by live staining of cells and found all cells are Tra-1-81 (Fig. 2A) and Tra-1-60 (not shown) positive, thus confirming iPSC purity and pluripotency.

Acknowledgment

The project described was supported by Award Number I21BX002215 (WX) from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The views expressed in this article are those of the authors and do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

References

Badcock, G., Pigott, C., Goepel, J., Andrews, P.W., 1999. The human embryonal carcinoma marker antigen TRA-60 is a sialylated keratan sulfate proteoglycan. Cancer Res. 59 (18), 4715–4719.

Carpenter, M.K., Rosler, E., Rao, M.S., 2003. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 5 (1), 79–88.

Chou, B.K., Mali, P., Huang, X., Ye, Z., Dowey, S.N., Resar, L.M., et al., 2011. Efficient human iPSC cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 21 (3), 518–529.

Fusaki, N., Ban, H., Nishiyama, A., Saieki, K., Hasegawa, M., 2009. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 85 (8), 348–362.

Hribar, K.C., Finlay, D., Ma, X., Qu, X., Ondeck, M.G., Chung, P.H., et al., 2015. Nonlinear 3D projection printing of concave hydrogel microstructures for long-term multicellular spheroid and embryoid body culture. Lab Chip 15 (11), 2421–2418.

Itoivovitz-Eldor, J., Schuldiner, M., Kapemti, D., Eden, A., Yanuka, O., Amit, M., et al., 2000. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 6 (2), 88–95.

Li, H.G., Zhi, Y.F., Asakawa, M., Kuma, H., Hiraoka, T., Ueda, Y., et al., 2000. A cytoplasmic RNA vector derived from non-transmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74 (14), 6564–6569.

Li, S.C., Jin, Y., Loudon, W.C., Song, Y., Ma, Z., Weiner, L.P., et al., 2011. Increase developmental plasticity of human keratinocytes with gene suppression. Proc. Natl. Acad. Sci. U. S. A. 108 (31), 12793–12798.

Lieu, P.T., Fontes, A., Vernuri, M.C., Macarthur, C.C., 2013. Generation of induced pluripotent stem cells with CytoTune, a non-integrating Sendai virus. Methods Mol. Biol. 997, 45–56.

Nethercott, H.E., Brick, D.J., Schwartz, P.H., 2011. Derivation of induced pluripotent stem cells by lentiviral transduction. Methods Mol. Biol. (Clifton, NJ) 767, 67–85.

Ovchinnikov, D.A., Sun, J., Wolvetang, E.J., 2015. Generation of footprint-free induced pluripotent stem cells from human fibroblasts using episomal plasmid vectors. Methods Mol. Biol. 1330, 37–45.

Seki, T., Yuasa, S., Oda, M., Gasahara, T., Yae, K., Kusumoto, D., et al., 2010. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7 (1), 11–14.

Sommer, A.G., Rozelle, S.S., Sullivan, S., Mills, J.A., Park, S.M., Smith, B.W., et al., 2012. Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. J. Vis. Exp. JoVE. 68, 4327.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (5), 861–872.

Trokovic, R., Weltner, J., Nishimura, K., Ohtaka, M., Nakashima, M., Salomaa, V., et al., 2014. Advanced feeder-free generation of induced pluripotent stem cells directly from blood cells. Stem Cells Transl. Med. 3 (12), 1402–1409.